Histological verification of 11C-choline-positron emission/computed tomography-positive lymph nodes in patients with biochemical failure after treatment for localized prostate cancer

BJU International

Volumn 102, Issue 4, 2008, Pages 446-451

  Schilling, David ^a   Schlemmer, Heinz P ^a   Wagner, Philipp H ^a   Böttcher, Patrick ^a   Merseburger, Axel S ^a   Aschoff, Philip ^a   Bares, Roland ^a   Pfannenberg, Christa ^a   Ganswindt, Ute ^a   Corvin, Stefan ^a   Stenzl, Arnulf ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Choline PET; Lymph node metastasis; Prostate cancer; PSA relapse

Indexed keywords

CHOLINE C 11; DOCETAXEL; PROSTATE SPECIFIC ANTIGEN; CARBON; CHOLINE; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BIOCHEMISTRY; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RELAPSE; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC VALUE; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HISTOPATHOLOGY; HORMONE INHIBITION; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LAPAROSCOPIC SURGERY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALIDITY; PRIORITY JOURNAL; PROSTATE CANCER; RADICAL RETROPUBIC PROSTATECTOMY; RECURRENT CANCER; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT PLANNING; TUMOR LOCALIZATION; WATCHFUL WAITING; ANALYSIS OF VARIANCE; BLOOD; CANCER STAGING; EVALUATION; LENGTH OF STAY; LYMPH NODE; METASTASIS; METHODOLOGY; PATHOLOGY; PREDICTION AND FORECASTING; PROSTATE TUMOR; PROSTATECTOMY; SALVAGE THERAPY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ANALYSIS OF VARIANCE; CARBON RADIOISOTOPES; CHOLINE; HUMANS; LENGTH OF STAY; LYMPH NODE EXCISION; LYMPH NODES; MALE; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOPHARMACEUTICALS; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SENSITIVITY AND SPECIFICITY;

EID: 47749151932     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2008.07592.x     Document Type: Article

References (24)

1. Morgan WR, Bergstralh EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology 1993 41 : 113 20
2. Stein A, de Kernion JB, Dorey F. Prostatic specific antigen related to clinical status 1-14 years after radical retropubic prostatectomy. Br J Urol 1991 67 : 626 31
3. Stamey TA, Ferrari MK, Schmid HP. The value of serial prostate specific antigen determinations 5 years after radiotherapy: steeply increasing values characterize 80% of patients. J Urol 1993 150 : 1856 9
4. Han M, Partin AW, Zahurak M, Piantadosi S, Epstein JI, Walsh PC. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. J Urol 2003 169 : 517 23
5. Lange PH, Winfield HN. Biological markers in urologic cancer. Cancer 1987 60 (Suppl. 464 72
6. Partin AW, Oesterling JE. The clinical usefulness of prostate specific antigen: update. J Urol 1994 152 : 1358 68
7. Bott SR. Management of recurrent disease after radical prostatectomy. Prostate Cancer Prostatic Dis 2004 7 : 211 6
8. Hara T, Kosaka N, Kishi H. PET imaging of prostate cancer using carbon-11-choline. J Nucl Med 1998 39 : 990 5
9. DeGrado TR, Coleman RE, Wang S et al. Synthesis and evaluation of 18F-labeled choline as an oncologic tracer for positron emission tomography: initial findings in prostate cancer. Cancer Res 2001 61 : 110 7
10. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. Preoperative staging of pelvic lymph nodes in prostate cancer by 11C-choline PET. J Nucl Med 2003 44 : 331 5
11. Langsteger W, Heinisch M, Fogelman I. The role of fluorodeoxyglucose, (18)F-dihydroxyphenylalanine, (18)F-choline, and (18)F-fluoride in bone imaging with emphasis on prostate and breast. Semin Nucl Med 2006 36 : 73 92
12. de Jong IJ, Pruim J, Elsinga PH, Vaalburg W, Mensink HJ. 11C-choline positron emission tomography for the evaluation after treatment of localized prostate cancer. Eur Urol 2003 44 : 32 8
13. Picchio M, Messa C, Landoni C et al. Value of [11C]choline-positron emission tomography for re-staging prostate cancer: a comparison with [18F]fluorodeoxyglucose-positron emission tomography. J Urol 2003 169 : 1337 40
14. Kotzerke J, Volkmer BG, Glatting G et al. Intraindividual comparison of [11C]acetate and [11C]choline PET for detection of metastases of prostate cancer. Nuklearmedizin 2003 42 : 25 30
15. Pound CR, Christens-Barry OW, Gurganus RT, Partin AW, Walsh PC. Digital rectal examination and imaging studies are unnecessary in men with undetectable prostate specific antigen following radical prostatectomy. J Urol 1999 162 : 1337 40
16. Moul JW. Prostate specific antigen only progression of prostate cancer. J Urol 2000 163 : 1632 42
17. Hoh CK, Schiepers C, Seltzer MA et al. PET in oncology: will it replace the other modalities? Semin Nucl Med 1997 27 : 94 106
18. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999 12 : 413 39
19. Hara T, Kosaka N, Shinoura N, Kondo T. PET imaging of brain tumor with [methyl-11C]choline. J Nucl Med 1997 38 : 842 7
20. Kotzerke J, Prang J, Neumaier B et al. Experience with carbon-11 choline positron emission tomography in prostate carcinoma. Eur J Nucl Med 2000 27 : 1415 9
21. Heinisch M, Dirisamer A, Loidl W et al. Positron emission tomography/computed tomography with F-18-fluorocholine for restaging of prostate cancer patients: meaningful at PSA <5 ng/mL? Mol Imaging Biol 2006 8 : 43 8
22. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006 354 : 496 507
23. Harisinghani MG, Barentsz J, Hahn PF et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 2003 348 : 2491 9
24. Scattoni V, Picchio M, Suardi N et al. Detection of lymph-node metastases with integrated [(11)C]choline PET/CT in patients with PSA failure after radical retropubic prostatectomy: results confirmed by open pelvic- retroperitoneal lymphadenectomy. Eur Urol 2007 52 : 423 9